Does the media favor RNXT or VTGN?

In the previous week, VistaGen Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for RenovoRx. VistaGen Therapeutics' average media sentiment score of 0.85 beat RenovoRx's score of 0.00 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend APLM or VTGN?

VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 304.26%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Which has preferable earnings and valuation, APLM or VTGN?

Apollomics has higher revenue and earnings than VistaGen Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 4.84 -$10.94M N/A N/A VistaGen Therapeutics $1.27M 7.60 -$69.68M -$1.83 N/A

Does the media prefer APLM or VTGN?

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Apollomics. VistaGen Therapeutics' average media sentiment score of 0.85 beat Apollomics' score of 0.30 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELUT or VTGN?

In the previous week, Elutia had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Elutia and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.85 beat Elutia's score of 0.33 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral VistaGen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IXHL or VTGN?

In the previous week, Incannex Healthcare and Incannex Healthcare both had 2 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.85 beat Incannex Healthcare's score of 0.59 indicating that VistaGen Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incannex Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive VistaGen Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

VistaGen Therapeutics (VTGN) Competitors

$0.24 +0.00 (+1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$0.24 +0.00 (+0.85%)

As of 06:30 PM Eastern

Compare

VTGN vs. RNXT, APLM, ELUT, ALGS, and IXHL

Should you buy VistaGen Therapeutics stock or one of its competitors? MarketBeat compares VistaGen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with VistaGen Therapeutics include RenovoRx (RNXT), Apollomics (APLM), Elutia (ELUT), Aligos Therapeutics (ALGS), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

How does VistaGen Therapeutics compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

RenovoRx has higher earnings, but lower revenue than VistaGen Therapeutics. RenovoRx is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	35.30	-$11.17M	-$0.33	N/A
VistaGen Therapeutics	$1.27M	7.60	-$69.68M	-$1.83	N/A

RenovoRx has a net margin of -823.98% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

RenovoRx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

RenovoRx presently has a consensus price target of $8.50, suggesting a potential upside of 868.55%. VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 304.26%. Given RenovoRx's stronger consensus rating and higher probable upside, equities research analysts plainly believe RenovoRx is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, VistaGen Therapeutics had 1 more articles in the media than RenovoRx. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for RenovoRx. VistaGen Therapeutics' average media sentiment score of 0.85 beat RenovoRx's score of 0.00 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

RenovoRx beats VistaGen Therapeutics on 11 of the 17 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Apollomics. VistaGen Therapeutics' average media sentiment score of 0.85 beat Apollomics' score of 0.30 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apollomics has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

VistaGen Therapeutics has a consensus target price of $0.95, suggesting a potential upside of 304.26%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Apollomics has higher revenue and earnings than VistaGen Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	4.84	-$10.94M	N/A	N/A
VistaGen Therapeutics	$1.27M	7.60	-$69.68M	-$1.83	N/A

19.1% of Apollomics shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Apollomics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. Apollomics' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

Summary

VistaGen Therapeutics beats Apollomics on 7 of the 13 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Elutia?

Elutia (NASDAQ:ELUT) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Elutia has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.46M	3.26	$53.38M	$0.86	1.10
VistaGen Therapeutics	$1.27M	7.60	-$69.68M	-$1.83	N/A

Elutia has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

74.0% of Elutia shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 17.8% of Elutia shares are held by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Elutia has a net margin of 312.09% compared to VistaGen Therapeutics' net margin of -5,487.01%. Elutia's return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

In the previous week, Elutia had 1 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Elutia and 2 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.85 beat Elutia's score of 0.33 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elutia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
VistaGen Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elutia presently has a consensus price target of $6.00, suggesting a potential upside of 531.58%. VistaGen Therapeutics has a consensus price target of $0.95, suggesting a potential upside of 304.26%. Given Elutia's stronger consensus rating and higher possible upside, research analysts clearly believe Elutia is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Elutia beats VistaGen Therapeutics on 13 of the 16 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Aligos Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Aligos Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$1.27M	7.60	-$69.68M	-$1.83	N/A
Aligos Therapeutics	$2.19M	15.38	-$24.19M	-$8.69	N/A

VistaGen Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the broader market.

VistaGen Therapeutics currently has a consensus target price of $0.95, suggesting a potential upside of 304.26%. Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 607.72%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Aligos Therapeutics has a net margin of -1,919.68% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

In the previous week, VistaGen Therapeutics had 2 more articles in the media than Aligos Therapeutics. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 0 mentions for Aligos Therapeutics. VistaGen Therapeutics' average media sentiment score of 0.85 beat Aligos Therapeutics' score of 0.00 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
VistaGen Therapeutics	Positive
Aligos Therapeutics	Neutral

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aligos Therapeutics beats VistaGen Therapeutics on 11 of the 17 factors compared between the two stocks.

How does VistaGen Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Incannex Healthcare has higher earnings, but lower revenue than VistaGen Therapeutics. Incannex Healthcare is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	426.93	-$46.88M	-$1.55	N/A
VistaGen Therapeutics	$1.27M	7.60	-$69.68M	-$1.83	N/A

Incannex Healthcare currently has a consensus price target of $18.00, indicating a potential upside of 460.75%. VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 304.26%. Given Incannex Healthcare's stronger consensus rating and higher possible upside, equities research analysts plainly believe Incannex Healthcare is more favorable than VistaGen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Incannex Healthcare has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. Incannex Healthcare's return on equity of -81.01% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

0.4% of Incannex Healthcare shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 1.3% of Incannex Healthcare shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Incannex Healthcare and Incannex Healthcare both had 2 articles in the media. VistaGen Therapeutics' average media sentiment score of 0.85 beat Incannex Healthcare's score of 0.59 indicating that VistaGen Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incannex Healthcare	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
VistaGen Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incannex Healthcare has a beta of 6.95, indicating that its stock price is 595% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

Summary

Incannex Healthcare beats VistaGen Therapeutics on 10 of the 15 factors compared between the two stocks.

Get VistaGen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VTGN vs. The Competition

Export

Metric	VistaGen Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.64M	$3.65B	$6.81B	$12.41B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.13	20.79	27.00	24.19
Price / Sales	7.60	320.27	517.85	93.08
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.26	8.17	10.67	6.26
Net Income	-$69.68M	$23.81M	$3.60B	$331.76M
7 Day Performance	-4.51%	-1.16%	-0.37%	-1.10%
1 Month Performance	-64.94%	2.59%	1.80%	-1.29%
1 Year Performance	-90.78%	45.43%	25.50%	18.84%

VistaGen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VTGN VistaGen Therapeutics	3.0421 of 5 stars	$0.24 +1.7%	$0.95 +304.3%	-90.9%	$9.64M	$1.27M	N/A	40
RNXT RenovoRx	3.3496 of 5 stars	$0.91 -1.8%	$8.50 +830.6%	-33.6%	$41.90M	$1.12M	N/A	6	Analyst Upgrade
APLM Apollomics	0.7858 of 5 stars	$14.21 -25.0%	N/A	+203.7%	$41.62M	$8.50M	N/A	45	High Trading Volume
ELUT Elutia	3.0216 of 5 stars	$0.92 -5.0%	$6.00 +555.7%	-56.1%	$41.20M	$12.29M	1.06	180
ALGS Aligos Therapeutics	2.8097 of 5 stars	$6.36 -3.9%	$38.50 +505.3%	-42.4%	$40.96M	$2.19M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VTGN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. RNXT, APLM, ELUT, ALGS, and IXHL

How does VistaGen Therapeutics compare to RenovoRx?

Summary

How does VistaGen Therapeutics compare to Apollomics?

Summary

How does VistaGen Therapeutics compare to Elutia?

Summary

How does VistaGen Therapeutics compare to Aligos Therapeutics?

Summary

How does VistaGen Therapeutics compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VistaGen Therapeutics (VTGN) Competitors

VTGN vs. RNXT, APLM, ELUT, ALGS, and IXHL

How does VistaGen Therapeutics compare to RenovoRx?

Which has stronger earnings and valuation, RNXT or VTGN?

Is RNXT or VTGN more profitable?

Which has more volatility and risk, RNXT or VTGN?

Do analysts recommend RNXT or VTGN?

Does the media favor RNXT or VTGN?

Do institutionals & insiders hold more shares of RNXT or VTGN?

Summary

How does VistaGen Therapeutics compare to Apollomics?

Does the media prefer APLM or VTGN?

Which has more volatility & risk, APLM or VTGN?

Do analysts recommend APLM or VTGN?

Which has preferable earnings and valuation, APLM or VTGN?

Do institutionals and insiders have more ownership in APLM or VTGN?

Is APLM or VTGN more profitable?

Summary

How does VistaGen Therapeutics compare to Elutia?

Which has better earnings and valuation, ELUT or VTGN?

Which has more risk & volatility, ELUT or VTGN?

Do insiders and institutionals have more ownership in ELUT or VTGN?

Is ELUT or VTGN more profitable?

Does the media favor ELUT or VTGN?

Do analysts prefer ELUT or VTGN?

Summary

How does VistaGen Therapeutics compare to Aligos Therapeutics?

Which has preferable valuation & earnings, VTGN or ALGS?

Which has more volatility and risk, VTGN or ALGS?

Do analysts recommend VTGN or ALGS?

Is VTGN or ALGS more profitable?

Does the media refer more to VTGN or ALGS?

Do institutionals & insiders hold more shares of VTGN or ALGS?

Summary

How does VistaGen Therapeutics compare to Incannex Healthcare?

Which has better valuation & earnings, IXHL or VTGN?

Do analysts rate IXHL or VTGN?

Is IXHL or VTGN more profitable?

Do institutionals and insiders hold more shares of IXHL or VTGN?

Does the media prefer IXHL or VTGN?

Which has more risk and volatility, IXHL or VTGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN vs. The Competition

VistaGen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools